Agomelatine: a new option for treatment of depression?

Bibliography

• Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: a premise and promise. Psychiatry Investig 2008;5:142-7
   PubMed Web of Science ®Google Scholar
• Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011;378:621-31
   PubMed Web of Science ®Google Scholar
• Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007;10:661-73
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006;16:93-100
   PubMed Web of Science ®Google Scholar
• Loo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17:239-47
   PubMed Web of Science ®Google Scholar
• Koesters M, Guaiana G, Cipriani A, et al. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 2013;203:179-87
   PubMed Web of Science ®Google Scholar
• Howland RH. Publication bias and outcome reporting bias: agomelatine as a case example. J Psychosoc Nurs Ment Health Serv 2011;49:11-14
   Google Scholar
• Kasper S, Corruble E, Hale A, et al. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. Int Clin Psychopharmacol 2013;28:12-19
   PubMed Web of Science ®Google Scholar
• Heun R, Ahokas A, Boyer P, et al. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry 2013;74:587-94
   PubMed Web of Science ®Google Scholar
• Kasper S, Hajak G. The efficacy of agomelatine in previously-treated depressed patients. Eur Neuropsychopharmacol 2013;23:814-21
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007;22:283-91
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Corruble E, Hale A, et al. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectr 2013;18:163-70
   PubMed Web of Science ®Google Scholar
• Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol 2011;1-12: In press
   Google Scholar
• Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf 2011;34:709-31
   PubMed Web of Science ®Google Scholar
• Melander H, Salmonson T, Abadie E, et al. A regulatory Apologia – a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 2008;18:623-7
   PubMed Web of Science ®Google Scholar
• Gahr M, Freudenmann RW, Connemann BJ, et al. Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions. Pharmacopsychiatry 2013;46:214-20
   PubMed Web of Science ®Google Scholar
• Malhi GS, Kuiper S. Chronobiology of mood disorders. Acta Psychiatr Scand Suppl 2013;444:2-15
   Google Scholar
• Boyce P, Hopwood M. Manipulating melatonin in managing mood. Acta Psychiatr Scand Suppl 2013;444:16-23
   Google Scholar
• Kuiper S, McLean L, Fritz K, et al. Getting depression clinical practice guidelines right: time for change? Acta Psychiatr Scand Suppl 2013;444:24-30
   Google Scholar
• Massart R, Mongeau R, Lanfumey L. Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression. Philos Trans R Soc Lond B Biol Sci 2012;367:2485-94
   PubMed Web of Science ®Google Scholar
• Mathews DC, Henter ID, Zarate CA. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs 2012;72:1313-33
   PubMed Web of Science ®Google Scholar
• Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013;170:1134-42
   PubMed Web of Science ®Google Scholar
• Milanese M, Tardito D, Musazzi L, et al. Chronic treatment with agomelatine or venlafaxine reduces depolarization-evoked glutamate release from hippocampal synaptosomes. BMC Neurosci 2013;14:75
   Google Scholar
• Tanti A, Belzung C. Neurogenesis along the septo-temporal axis of the hippocampus: are depression and the action of antidepressants region-specific? Neuroscience 2013;252:234-52
   PubMed Web of Science ®Google Scholar
• Aguiar C, Almeida A, Araújo P, et al. Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures. Cell Mol Neurobiol 2013;825-35
   Google Scholar
• Schmelting B, Corbach-Sohle S, Kohlhause S, et al. Agomelatine in the tree shrew model of depression: effects on stress-induced nocturnal hyperthermia and hormonal status. Eur Neuropsychopharmacol 2013; In press
   Google Scholar
• Corruble E, Frank E, Gressier F, et al. Morningness-eveningness and treatment response in major depressive disorder. Chronobiol Int 2013; In press
   Google Scholar